New York, NY -- (SBWIRE) -- 12/13/2013 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Zogenix, Inc (NASDAQ:ZGNX), Arena Pharmaceuticals, Inc (NASDAQ:ARNA), Baxano Surgical Inc (NASDAQ:BAXS), Hercules Offshore, Inc (NASDAQ:HERO)
Zogenix, Inc (NASDAQ:ZGNX) showed a volume of 2.99 million shares by the end of last trade whereas the average volume of the stock remained 2.25 million shares. The stock opened the session at $2.95 but then moved to $3.02. At that price, the stock showed a positive performance of 0.67%. Zogenix, Inc. (Zogenix) is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. The Company’s product Sumavel DosePro offers needle-free subcutaneous administration of sumatriptan for the treatment of migraine and cluster headache in a pre-filled, single-use delivery system. Its lead product candidate, Zohydro (hydrocodone bitartrate, formerly ZX002) is a 12-hour extended-release formulation of hydrocodone without acetaminophen for the treatment of chronic pain requiring opioid therapy. It completed Phase 3 development of Zohydro in 2011.
Will ZGNX Continue To Move Higher? Find Out Here
Arena Pharmaceuticals, Inc (NASDAQ:ARNA) opened the session at $5.66 and closed the session at $5.77. The stock showed a positive performance of 2.12% in previous trading session. Traded with volume of 2.92 million shares in the prior session and the average volume of the stock remained 5.91 million shares. Baxano Surgical Inc, formerly TranS1 Inc., is a medical device company focused on designing, developing and marketing products that implement its approach to treat degenerative conditions of the spine affecting the lower lumbar region. It develops its pre-sacral approach to allow spine surgeons to access and treat intervertebral spaces without compromising important surrounding soft tissue, nerves and bone structures.
For How Long ARNA will fight for Profitability? Read This Trend Analysis report
Baxano Surgical Inc (NASDAQ:BAXS) opened the session at $1.14 and closed the session at $1.09. The stock showed a positive performance of 13.54% in previous trading session. Traded with volume of 2.92 million shares in the prior session and the average volume of the stock remained 159,420.00 shares. The beta of the stock remained 0.57. Arena Pharmaceuticals, Inc. (Arena) is a biopharmaceutical company focused on discovering, developing and commercializing drugs that target G protein-coupled receptors. Its wholly owned subsidiary, Arena Pharmaceuticals GmbH (Arena GmbH), has granted Eisai Inc., rights to commercialize BELVIQ in the United States. The Company’s oral drug candidates include APD811, an agonist of the prostacyclin receptor intended for the treatment of pulmonary arterial hypertension, which is in Phase I; temanogrel,
Why Should Investors Buy BAXS After The Recent Gain? Just Go Here and Find Out
Hercules Offshore, Inc (NASDAQ:HERO) the stock advanced 2.56% and finished the session at $6.01. Traded with volume of 2.83 million shares in the prior session and the average volume of the stock remained 2.83 million shares. The beta of the stock remained 3.40. Hercules Offshore, Inc. (Hercules Offshore) provides shallow-water drilling and marine services to the oil and natural gas exploration and production industry globally. It provides these services to national oil and gas companies, integrated energy companies and independent oil and natural gas operators. As of February 23, 2012,
Will HERO Continue To Move Higher? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)